InvestorsHub Logo
Followers 26
Posts 3320
Boards Moderated 21
Alias Born 08/18/2006

Re: PJO post# 767

Sunday, 02/04/2018 11:51:04 AM

Sunday, February 04, 2018 11:51:04 AM

Post# of 1461
official company announcement...I follow the company

maybe you should do the same...if you are invested in this company or plan to do so...

Although both the 9 mg and 18 mg cohorts met the primary efficacy endpoint in the Phase 2 clinical trial, after evaluating the drug development environment for breast cancer, where treatment paradigms are shifting to immunotherapies and/or combination therapies, the Company has decided that the time and cost of conducting the necessary clinical trials for approval in this indication do not warrant further development of enobosarm in this indication at this time.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCT News